Biosimilars: Are they the same quality?

What are biologics?
Biologics (also called biological products) include a wide range of products such as vaccines, monoclonal antibodies, blood components, allergens, gene therapy, tissues, and proteins. They generally come from living organisms, which can include animal cells and microorganisms, such as yeast and bacteria. They are used to treat a variety of diseases and conditions, such as cancer, kidney diseases, and autoimmune diseases.

Biologics are medicines that are made from living organisms, which can include animal cells and microorganisms, such as yeast and bacteria. They are used to treat a variety of diseases and conditions, such as cancer, kidney diseases, and autoimmune diseases.

What are biosimilars?
A biosimilar is a biologic that is highly similar to another biologic that’s already FDA-approved, called a reference product. Biosimilars have no clinically meaningful differences from their reference product in terms of safety, purity, and potency.

Biosimilars have the same:
- Route of administration to patients
- Strength and dosage form
- Potential side effects

Biosimilars are approved for many biologic reference products, including:
- Avastin
- Humira
- Herceptin
- Lucentis
- Remicade
- Epogen/Procrit
- Neulasta
- Rituxan
- Enbrel
- Lantus
- Neupogen

Biosimilars can improve patient access to quality medicines
Biosimilars are versions of brand name biologics that may offer more affordable treatment options to patients, similar to generic drugs.

Understanding the quality of biosimilar products
Biosimilars are:
Rigorously tested by their manufacturers following the same robust quality assessments as their reference products. These assessments are performed in accordance with the Current Good Manufacturing Practice regulations enforced by FDA.

What steps are involved to help ensure quality biosimilars?

Extensive research and comparative studies by the manufacturer to demonstrate high similarity to the reference product.

Studies directly comparing the biosimilar to the reference product to demonstrate no clinically meaningful differences in safety, purity, and potency.

FDA review of data required for approval of a biosimilar.

FDA inspections of the biosimilar manufacturing facilities.

Post-market drug safety surveillance by FDA and biosimilar manufacturers.

Learn more
www.usp.org/about/convention-membership
www.fda.gov/drugs/biosimilars/patient-materials

References
1 www.fda.gov/biosimilars